<qa>  What is the name of the treatment subjects will be given to the investigator?Subjects with persistent erythema due to rosacea will be recruited from the Wake Forest Baptist Health Dermatology Clinic and IRB approved advertising. At the baseline screening visit, subjects will have the diagnosis of rosacea confirmed by an investigator. Subjects will be classified as having erythematotelangiectatic or a combination erythematotelangiectatic and papulopustular. The Investigator will evaluate whether subjects believe they have constant erythema or more intermittent flushing and blushing. Subjects will be informed of the benefits and risks of treatment as indicated in the package insert. If they agree to participate, the subjects will give written consent approved by the Institutional Review Board and will be seen in follow up at 3 months and 6 months. 